Drug
PCI-32765 (Ibrutinib)
PCI-32765 (Ibrutinib) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (50.0%)
Phase 31 (50.0%)
Trials by Status
completed267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
NCT01974440
completedphase_2
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
NCT01779791
unknown
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02437019
Clinical Trials (3)
Showing 3 of 3 trials
NCT01974440Phase 3
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
NCT01779791Phase 2
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
NCT02437019
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3